

Panu K Luukkonen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8179500/publications.pdf>

Version: 2024-02-01

32
papers

2,276
citations

393982

19
h-index

433756

31
g-index

34
all docs

34
docs citations

34
times ranked

3230
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2016, 64, 1167-1175.	1.8	342
2	Saturated Fat Is More Metabolically Harmful for the Human Liver Than Unsaturated Fat or Simple Sugars. <i>Diabetes Care</i> , 2018, 41, 1732-1739.	4.3	266
3	Quantitative PCR provides a simple and accessible method for quantitative microbiota profiling. <i>PLoS ONE</i> , 2020, 15, e0227285.	1.1	207
4	The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans. <i>Journal of Hepatology</i> , 2016, 65, 1263-1265.	1.8	140
5	Effect of a ketogenic diet on hepatic steatosis and hepatic mitochondrial metabolism in nonalcoholic fatty liver disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 7347-7354.	3.3	137
6	Dietary carbohydrates and fats in nonalcoholic fatty liver disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 770-786.	8.2	108
7	Exposure to environmental contaminants is associated with altered hepatic lipid metabolism in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2022, 76, 283-293.	1.8	106
8	Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD. <i>Journal of Hepatology</i> , 2017, 67, 128-136.	1.8	97
9	Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids. <i>JCI Insight</i> , 2019, 4, .	2.3	93
10	LPIAT1/MBOAT7 depletion increases triglyceride synthesis fueled by high phosphatidylinositol turnover. <i>Gut</i> , 2021, 70, 180-193.	6.1	86
11	A Membrane-Bound Diacylglycerol Species Induces PKC β -Mediated Hepatic Insulin Resistance. <i>Cell Metabolism</i> , 2020, 32, 654-664.e5.	7.2	83
12	Exome-Wide Association Study on Alanine Aminotransferase Identifies Sequence Variants in the GPAM and APOE Associated With Fatty Liver Disease. <i>Gastroenterology</i> , 2021, 160, 1634-1646.e7.	0.6	82
13	Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2022, 76, 526-535.	1.8	80
14	rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis. <i>Journal of Hepatology</i> , 2021, 74, 20-30.	1.8	77
15	Hydroxysteroid 17- β dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease. <i>JCI Insight</i> , 2020, 5, .	2.3	62
16	MARC1 variant rs2642438 increases hepatic phosphatidylcholines and decreases severity of non-alcoholic fatty liver disease in humans. <i>Journal of Hepatology</i> , 2020, 73, 725-726.	1.8	39
17	Continuous Grading of Early Fibrosis in NAFLD Using Label-Free Imaging: A Proof-of-Concept Study. <i>PLoS ONE</i> , 2016, 11, e0147804.	1.1	34
18	Impact of short-term overfeeding of saturated or unsaturated fat or sugars on the gut microbiota in relation to liver fat in obese and overweight adults. <i>Clinical Nutrition</i> , 2021, 40, 207-216.	2.3	28

#	ARTICLE	IF	CITATIONS
19	Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e2008-e2020.	1.8	27
20	Development and validation of a model to predict incident chronic liver disease in the general population: The CLivD score. <i>Journal of Hepatology</i> , 2022, 77, 302-311.	1.8	21
21	Predictors of Liver Fat and Stiffness in Non-Alcoholic Fatty Liver Disease (NAFLD) – an 11-Year Prospective Study. <i>Scientific Reports</i> , 2017, 7, 14561.	1.6	18
22	Obesity/insulin resistance rather than liver fat increases coagulation factor activities and expression in humans. <i>Thrombosis and Haemostasis</i> , 2017, 117, 286-294.	1.8	18
23	The PNPLA3-I148M variant increases polyunsaturated triglycerides in human adipose tissue. <i>Liver International</i> , 2020, 40, 2128-2138.	1.9	17
24	The PNPLA3-I148M Variant Confers an Antiatherogenic Lipid Profile in Insulin-resistant Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e300-e315.	1.8	17
25	Heterogeneity of non-alcoholic fatty liver disease. <i>Liver International</i> , 2015, 35, 2498-2500.	1.9	15
26	PSD3 downregulation confers protection against fatty liver disease. <i>Nature Metabolism</i> , 2022, 4, 60-75.	5.1	15
27	Overfeeding Saturated Fat Increases LDL (Low-Density Lipoprotein) Aggregation Susceptibility While Overfeeding Unsaturated Fat Decreases Proteoglycan-Binding of Lipoproteins. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 2823-2836.	1.1	12
28	The Pi*—MZ Allele in Alpha-1 Antitrypsin Increases Liver-Related Outcomes in a Population-Based Study. <i>Gastroenterology</i> , 2021, 160, 1874-1875.	0.6	10
29	Assessment of Lifestyle Factors Helps to Identify Liver Fibrosis Due to Non-Alcoholic Fatty Liver Disease in Obesity. <i>Nutrients</i> , 2021, 13, 169.	1.7	9
30	Diabetes, Liver Cancer, and Cirrhosis: What Next?. <i>Hepatology</i> , 2018, 68, 1220-1222.	3.6	6
31	Natural Course of Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Patients With Human Immunodeficiency Virus With and Without Combination Antiretroviral Therapy—associated Lipodystrophy: A 16-Year Follow-up Study. <i>Clinical Infectious Diseases</i> , 2020, 70, 1708-1716.	2.9	6
32	Validation of the Chronic Liver Disease (CLivD) score. <i>Journal of Hepatology</i> , 2022, , .	1.8	0